We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study.
- Authors
Hjorth, Martin; Hjertner, Øyvind; Knudsen, Lene Meldgaard; Gulbrandsen, Nina; Holmberg, Erik; Pedersen, Per Trøllund; Andersen, Niels Frost; Andréasson, Björn; Billström, Rolf; Carlson, Kristina; Carlsson, Margaretha S; Flogegård, Max; Forsberg, Karin; Gimsing, Peter; Karlsson, Torbjörn; Linder, Olle; Nahi, Hareth; Othzén, Annika; Swedin, Agneta; Nordic Myeloma Study Group (NMSG)
- Abstract
Thalidomide and bortezomib have been frequently used for second-line therapy in patients with myeloma relapsing after or refractory to initial melphalan-based treatment, but no randomized trials have been published comparing these two treatment alternatives.
- Publication
European journal of haematology, 2012, Vol 88, Issue 6, p485
- ISSN
1600-0609
- Publication type
Journal Article
- DOI
10.1111/j.1600-0609.2012.01775.x